Denotivir is an organic chemical compound with antiviral activity. In vitro antiviral activity of denotivir has been demonstrated against human HSV types 1 and 2, and varicella zoster virus (VZV). Clinical trials with vratizolin have given impressive results in the patients with local HSV infections and very good results in VZV infections. Genital herpes, a sexually transmitted HSV infection, whose incidence is increasing and whose treatment has never been adequate, appears to respond well to the treatment with vratizolin with very good results. Very good therapeutic results were also obtained by applying vratizolin to the patients with an ophthalmic HSV infection. Vratizolin exerted strong immunosuppressive actions. Vratizolin inhibited to some degree LPS-induced cytokine production in human peripheral blood cultures. The activities of TNF-alpha, IL-1 and IL-6 were inhibited on average by 37, 26 and 35%, respectively.